Abstract
Introduction
The renin-angiotensin system (RAS) has an important role in cardiovascular disease; angiotensinconverting enzyme (ACE) inhibitors are of proven benefit in reducing morbidity, mortality and in the prevention of cardiovascular disease. [1] [2] [3] [4] Studying endothelial function and dysfunction is a useful surrogate to predict the risk of future atherosclerotic events and venous occlusion plethysmography is an established methodology to study the endothelium and vascular function. 5 Using this technique, ACE inhibitors (ACE-Is) have been shown to reverse the endothelial dysfunction in normal subjects, 6 in smokers, 7 in insulin dependent diabetes mellitus, 8 in hypertension, 9 in coronary artery disease 10 and in heart failure.
11
One possible mechanism by which ACE-Is may exert this effect is by blocking the production of angiotensin II (Ang II), which has been shown to promote the formation of superoxide anions, which increase nitric oxide (NO) degradation. 12 ACE-Is also inhibit the breakdown of bradykinin, which increases the release of NO and the improved endothelial-dependent vasodilator response may result from this mechanism. 13, 14 Ang II receptor blockers (ARBs) have also been shown to improve stimulated endothelial function in non-insulin dependent diabetes mellitus, 15 hypertension 16 and coronary artery disease, 17 but there are as yet no studies in normal man to see if the beneficial effect of losartan is limited to those who already have cardiovascular risk factors and/or oxidative stress, or whether it would occur in all individuals, including normal volunteers. If it did, it implies that basal Ang II levels exert a deleterious effect on endothelial function even in normal man. Endothelial function is traditionally measured by the differential response to the vasodilators acetylcholine and nitroprusside, but what may be more important clinically are basal levels of NO bioactivity. Currently, it is unclear whether ARBs increase basal tonic levels of NO. Two previous studies found such an effect, 16, 18 while one study did not, 15 but all these studies were in patients with cardiovascular disease or risk factors and there is no information available in normal man. Clarification of this issue in particular is therefore required, since basal NO activity is probably more physiologically relevant than the traditional way of studying endothelial function. The traditional method infuses pharmacological doses of acetylcholine to increase forearm blood flow by 300-400%, which is obviously an artificial stimulus. The objectives of this study were twofold: firstly to study the effect of losartan on endothelial function in young male healthy volunteers and secondly, and more importantly, to study its effects on basal NO in normal man. If losartan
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has an effect on basal NO, this would imply that basal levels of Ang II act tonically to decrease basal levels of NO even in salt-replete man, in whom Ang II levels are low and generally thought to exert little or no biological effect.
Methods

Study population and protocol
Twenty-four non-smoking, male volunteers were recruited and gave written informed consent to participate in this study, which was approved by the Tayside Medical Ethics Committee and in accordance with the Helsinki Declaration (revised 1983). None had evidence of cardiovascular disease, as determined by history or clinical examination. Exclusion criteria for the study are displayed in Table 1 and subject characteristics in Table 2 . At a screening visit, ECG and baseline haematology was performed. At all visits, biochemical analysis was performed, including renal function, fasting glucose, liver function tests and lipid profile. Blood pressure (BP) measurements were recorded at baseline and throughout each study day. After initial screening, each volunteer entered a randomised, placebo-controlled, doubleblind crossover study comparing the effect of 50 mg losartan daily (one month) vs. placebo (one month). There was a washout period of at least two weeks between treatments. The author was not involved in the randomisation, which was done by a second investigator. Subjects attended for two 4-hour study mornings, during which vascular endothelial function was assessed by bilateral forearm venous occlusion plethysmography. 19 The following intra-arterial infusions were employed: Acetylcholine (Miochol CIBA Vision, Southampton, UK) to test endothelial-dependent vasodilatation at three concentrations (25, 50 and 100 nmol/ml). 20 Sodium Nitroprusside (David Bull Laboratories, UK) to test endothelial-independent vasodilatation was infused at three concentrations (4.2, 12.6 and 37.8 nmol/ml). 21 Owing to its known photosensitivity, sodium nitroprusside was protected from light throughout the study. N G -monomethyl-L-arginine (LNMMA) (Clinalfa, Switzerland) was infused at three concentrations, (1, 2 and 4 umol/ml).
All solutions were prepared immediately prior to use; sodium nitroprusside was dissolved in 5% glucose, while all other solutions were dissolved in 0.9% sodium chloride. Saline was also used to establish baseline blood flows and as the washout solution between drug infusions. Each dose was infused for five minutes to produce a cumulative dose-response curve.The infusion rates were kept constant at 1 ml/min throughout the study period (Braun Perfusor Secura pump, Melsungen, Germany).
Statistical analysis Haemodynamic and biochemical data
Comparisons between the biochemical parameters at baseline and follow-up were performed using paired Students t-test. Results were expressed as mean + standard deviation (SD).
Blood flow responses
The raw blood flow data in response to the vasoactive agents was converted to the ratio of the increase or decrease in blood flow in the cannulated arm over the blood flow in the control arm, according to the method of Greenfield and Patterson. 22 The result is expressed as the percentage change in forearm blood flow (FBF) from the baseline immediately preceding each drug administration (mean + standard error of mean [SEM]). 23 Measurements for individual subjects were compared between treatments by multiple analysis of variance (MANOVA) and the Bonferroni method for calculating 95% confidence intervals, correcting for multiple comparisons. 
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Results
There were no significant differences between biochemical parameters, baseline BP and heart rate between the two treatment visits. Subject characteristics are described in Table 2 . Crucially, basal BP was not significantly altered by losartan. Serum Ang II was significantly increased following treatment with losartan, confirming compliance (67+10 pg/ml (losartan) vs. 21+11 pg/ml (placebo); p=0.005).There was a trend towards a greater response to acetylcholine during losartan treatment, which did not reach significance. The mean percentage change in FBF [mean + SEM], was 214+20% for losartan vs. 174+20% for placebo; p=0.15 ( Figure 1 ). There was no difference in the response to FBF to the endothelialindependent vasodilator, sodium nitroprusside, between visits, (172+15% losartan vs. placebo 176+16%; p=0.84). The response to the endothelial-dependent vasoconstrictor, LNMMA, reached significance, with an increased mean vasoconstrictor response in the losartan-treated group (-37+2% vs. placebo -32+2%; p=0.05) (Figure 2 ). Absolute FBF values are shown in Table 3 ; there were no significant differences between the baseline values between visits and between the baseline value and washout values.
Discussion
The principal finding of this study is that losartan improves basal NO bioactivity in a group of nonsmoking, healthy, salt-replete volunteers. There was a significant increase in vasoconstriction to LNMMA, which suggests an improvement in basal NO bioactivity. A trend towards an improvement in acetylcholine-induced vasodilation was also demonstrated, which suggests that our LNMMA results were not by chance. The lack of effect of losartan on the control vasodilator, sodium nitroprusside, suggests an effect specific to endothelial NO. Indeed, the fact that our LNMMA data was more significant than our acetylcholine data supports this, since LNMMA is specific for NO while acetylcholine also acts via many non-NO routes, including bradykinin and prostaglandins. NO is likely to play a crucial role as the final common pathway of endothelial dysfunction through its pivotal role in the maintenance of the basal vascular state. NO interacts with a large number of other vasodilatory and vasoconstricting factors, including the RAS.Two studies demonstrated reduced endothelial function in individuals with certain adverse polymorphisms in the RAS, 24, 25 which is consistent with our observation that tonic levels of basal Ang II can exert adverse effects on the endothelium.
Previous data with other therapies would suggest that the beneficial effects which we have seen on endothelial function in the brachial artery are likely to be mirrored by similar changes in other vascular beds and are likely to be associated with reduced cardiovascular events. Several papers now show a link between endothelial dysfunction and future cardiac events, including one using forearm endothelial dysfunction. [26] [27] [28] There are also several treatments whose effect on endothelial dysfunction is paralleled by an effect on future cardiovascular events. For example, statins, 29 ACE-Is 10 and spironolactone 30 improve both, while the effect of vitamin E is usually neutral on both endothelial function and clinical events. 31, 32 The only treatment so far for which there is a dissociation between the effect on endothelial function and the effect on cardiac events is hormone replacement therapy. However, taken as a whole, our observation raises the distinct possibility that the beneficial effects which we describe may translate into beneficial effects in other arteries and perhaps even in cardiovascular events in the long term.
ACE-Is are the established treatment for many cardiovascular pathologies and improve endothelial dysfunction in a wide spectrum of conditions. antihypertensives on endothelial function 33, 34 and the improvement in endothelial function with ACE-Is is not dependent on the BP-lowering effect. 35 However, this is a controversial issue. In fact, the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 36 is the best evidence for a vasculoprotective effect of withdrawing Ang II.
The likely mechanism for the losartan/NO interaction seen here is that Ang II increases oxidative stress through its effects on NAD(P)H oxidase 12 and the production of superoxide anion. Losartan has been shown to reverse this increased production. 37 Additionally, superoxide anion interacts with NO to form peroxynitrite, which produces further strong oxidant species 38 and promotes the oxidation of lipid, 39 protein and other macromolecules. Enhanced inactivation of NO by superoxide is now considered to be a major mechanism for depression of NO-related endothelial function. 40 Endothelial dysfunction is associated with reduced bioavailability of NO and it has been demonstrated, in conditions of reduced NO, that the vasoconstrictor effect of Ang II is enhanced. 41 The same study demonstrated an attenuation of the vasoconstrictor response to Ang II by vitamin C, which suggests that the effect of Ang II is partly mediated through its effect on free radicals. The antioxidant, vitamin C, has been demonstrated to improve endothelial dysfunction in subjects with cardiovascular risk factors [42] [43] [44] [45] and in patients with chronic heart failure 46 and coronary artery disease. 47 Part of the benefit of antagonism of the RAS may arise from these antioxidant effects.
To complicate matters further, it is now recognised that some of the effect of ARBs may also be related to bradykinin through increased AT 2 -receptor stimulation, 48, 49 although it is thought that their main mechanism of action is through the reduction of NADH oxidase-mediated superoxide anion formation. 50 However, an alternative possibility to explain our results is that losartan caused endogenous Ang II to preferentially stimulate AT 2 -receptors, which increased bradykinin.
In conclusion, losartan improves tonic NO vascular activity in normal man. Such an effect has also been seen in two other studies involving hypertensive patients and patients with coronary artery disease, 16, 18 although not in one study of diabetics. 15 Our main finding is that even in saltreplete normal man, losartan increased basal NO bioactivity, which shows intriguingly that tonic levels of Ang II are acting to reduce tonic basal levels of NO, even in the absence of any cardiovascular risk factors. This even appears to occur where basal plasma Ang II levels are well into the normal range, indeed in the range where Ang II was previously thought to be virtually inactive.
